Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Stanbery

Showing results (21-30 of 47) with videos related to

Pageof 5
Sort By:
Vaccines|October 26, 2021
Case Report: Marked Survival Advantage of Two Colorectal Cancer Patients with Liver Metastases Treated with Vigil and FOLFOX-6Vedin Barve, Ned Adams, Laura Stanbery, et al.
Cancer Gene Therapy|November 17, 2021
Network based analysis identifies TP53m-BRCA1/2wt-homologous recombination proficient (HRP) population with enhanced susceptibility to Vigil immunotherapyElyssa Sliheet, Molly Robinson, Susan Morand, et al.
Future Oncology (London, England)|March 17, 2021
The abscopal effect of radiation therapyDaniel J Craig, Nisha S Nanavaty, Monika Devanaboyina, et al.
Cancer Treatment and Research Communications|January 10, 2022
Subclonal landscape of cancer drives resistance to immune therapyDaniel J Craig, Morgan M Bailey, Olivia B Noe, et al.
Journal of Clinical Medicine|September 28, 2023
Advances in Targeted Therapy for the Treatment of Cervical CancerDean E Watkins, Daniel J Craig, Shahnaz D Vellani, et al.
BMC Cancer|October 29, 2021
Homologous recombination proficiency in ovarian and breast cancer patientsJustin Fortune Creeden, Nisha S Nanavaty, Katelyn R Einloth, et al.
Scientific Reports|March 14, 2025
Exome sequencing shows same pattern of clonal tumor mutational burden, intratumor heterogenicity and clonal neoantigen between autologous tumor and Vigil productDavid Willoughby, Ernest Bognar, Laura Stanbery, et al.
Vaccines|October 6, 2020
Resident Memory T Cells and Their Effect on CancerDaniel J Craig, Justin F Creeden, Katelyn R Einloth, et al.
Cancers|December 9, 2023
Clonal Neoantigen: Emerging "Mechanism-based" Biomarker of Immunotherapy ResponseJohn Nemunaitis, Laura Stanbery, David Willoughby, et al.
The Journal of Gene Medicine|May 26, 2026
In Vivo Assessment of dbDNA GNE<sup>wt</sup>/bi-shRNA-GNE<sup>M743T</sup> Lipoplex for GNE Myopathy: Improved Potency and SafetyChristopher M Jay, Fabienne Kerneis, Donald Rao, et al.
Pageof 5

Showing results (21-30 of 47) with videos related to

Sort By:
Pageof 5
Vaccines|October 26, 2021
Case Report: Marked Survival Advantage of Two Colorectal Cancer Patients with Liver Metastases Treated with Vigil and FOLFOX-6Vedin Barve, Ned Adams, Laura Stanbery, et al.
Cancer Gene Therapy|November 17, 2021
Network based analysis identifies TP53m-BRCA1/2wt-homologous recombination proficient (HRP) population with enhanced susceptibility to Vigil immunotherapyElyssa Sliheet, Molly Robinson, Susan Morand, et al.
Future Oncology (London, England)|March 17, 2021
The abscopal effect of radiation therapyDaniel J Craig, Nisha S Nanavaty, Monika Devanaboyina, et al.
Cancer Treatment and Research Communications|January 10, 2022
Subclonal landscape of cancer drives resistance to immune therapyDaniel J Craig, Morgan M Bailey, Olivia B Noe, et al.
Journal of Clinical Medicine|September 28, 2023
Advances in Targeted Therapy for the Treatment of Cervical CancerDean E Watkins, Daniel J Craig, Shahnaz D Vellani, et al.
BMC Cancer|October 29, 2021
Homologous recombination proficiency in ovarian and breast cancer patientsJustin Fortune Creeden, Nisha S Nanavaty, Katelyn R Einloth, et al.
Scientific Reports|March 14, 2025
Exome sequencing shows same pattern of clonal tumor mutational burden, intratumor heterogenicity and clonal neoantigen between autologous tumor and Vigil productDavid Willoughby, Ernest Bognar, Laura Stanbery, et al.
Vaccines|October 6, 2020
Resident Memory T Cells and Their Effect on CancerDaniel J Craig, Justin F Creeden, Katelyn R Einloth, et al.
Cancers|December 9, 2023
Clonal Neoantigen: Emerging "Mechanism-based" Biomarker of Immunotherapy ResponseJohn Nemunaitis, Laura Stanbery, David Willoughby, et al.
The Journal of Gene Medicine|May 26, 2026
In Vivo Assessment of dbDNA GNE<sup>wt</sup>/bi-shRNA-GNE<sup>M743T</sup> Lipoplex for GNE Myopathy: Improved Potency and SafetyChristopher M Jay, Fabienne Kerneis, Donald Rao, et al.
Pageof 5